Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | YAP1 | P46937 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23869608 | 0.94 | MEN1 (0.52) | MEN1KMT2AHTTTACR1OPRD1 | |
| SCHEMBL18154336 | 0.86 | ALDH1A1 (0.43) | MEN1KMT2AHTTOPRK1NPC1 | |
| SCHEMBL551650 | 0.84 | MEN1 (0.48) | MEN1KMT2ATACR1OPRD1OPRK1 | |
| SCHEMBL28983642 | 0.82 | MEN1 (0.53) | MEN1KMT2AHTTTACR1OPRD1 | |
| SCHEMBL3492937 | 0.81 | MEN1 (0.51) | MEN1KMT2AHTTTACR1OPRD1 | |
| SCHEMBL30996003 | 0.81 | TSHR (0.47) | MEN1KMT2ATACR1OPRD1OPRK1 | |
| SCHEMBL3104656 | 0.81 | MEN1 (0.50) | MEN1KMT2AHTTTACR1OPRD1 | |
| SCHEMBL15878183 | 0.80 | MEN1 (0.44) | MEN1KMT2ATACR1OPRD1OPRK1 | |
| SCHEMBL15797644 | 0.80 | MEN1 (0.44) | MEN1KMT2ATACR1OPRD1OPRK1 | |
| SCHEMBL15796942 | 0.80 | MEN1 (0.44) | MEN1KMT2ATACR1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-09-17 | — | — | US | disclosed |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885HTT 4852/4885 |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885HTT 4852/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | MEN1 3255/4885KMT2A 3288/4885HTT 4846/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885HTT 4852/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | MEN1 1952/4885KMT2A 2513/4885HTT 4840/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885HTT 4852/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | MEN1 3290/4885KMT2A 3363/4885HTT 4853/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885HTT 4852/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885HTT 4852/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | MEN1 1865/4885KMT2A 2693/4885HTT 4847/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | MEN1 1952/4885KMT2A 2513/4885HTT 4840/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885HTT 4852/4885 |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885HTT 4852/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885HTT 4852/4885 |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | MEN1 1952/4885KMT2A 2513/4885HTT 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.